Citigroup
SKBI

Citigroup’s SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) SKBI Stock Holding History

Citigroup’s Portfolio SKBI Stock Details SKBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-818
Closed -$3K – 7677
2014
Q4 		$3K Buy
+818
New +$3.53K ﹤0.01% 6827
2014
Q2 		– Sell
-1,303
Closed -$9K – 7514
2014
Q1 		$9K Buy
+1,303
New +$6.59K ﹤0.01% 6407

Other funds holding SKBI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
CAM
ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's SKBI Position: Q1 2015 in Review

Citigroup sold out of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) in Q1 2015, closing a stake of 818 shares — an estimated $3K sold.

Citigroup first reported a position in SKBI in Q1 2014 and held it in 2 quarters. The position peaked at $9K in Q1 2014. 15 funds tracked by Wall St. Rank hold SKBI as of Q1 2015.

  • Citigroup reported no remaining SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position as of Q1 2015 after selling out during the quarter.
  • Citigroup sold 818 SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) shares in Q1 2015, an estimated $3K.
  • Citigroup first reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in Q1 2014 and held it in 2 quarters.
  • Citigroup's SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position peaked at $9K in Q1 2014.
  • 15 funds tracked by Wall St. Rank held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) as of Q1 2015.

Based on Citigroup's 13F filing for Q1 2015, filed 14 May 2015.